Journal
CANCER INVESTIGATION
Volume 27, Issue 2, Pages 221-226Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/07357900802208608
Keywords
Osteonecrosis of the jaw; Bisphosphonates; Anti-angiogenesis; Chemotherapy; Prostate pancer
Categories
Funding
- National Cancer Institute
- Center for Cancer Research
- National Institutes of Health
Ask authors/readers for more resources
ONJ is an important toxicity in cancer patients receiving bisphosphonate therapy. Here we report a higher than usual incidence of ONJ, 11 of 60 (18.3%, 95% Confidence Interval, CI: 9%-28%) patients enrolled in a phase II clinical trial combining bevacizumab, docetaxel, thalidomide, and prednisone (ATTP) in chemotherapy-naive men with metastatic castration resistant prostate cancer (mCRPC). The use of bisphosphonates was allowed at study entry. Our study suggests that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid. Imaging modalities, such as bone scans, may be useful in following the clinical course of patients who develop ONJ.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available